The fat mouse. A powerful genetic model to study Hemostatic gene expression in obesity/NIDDM

Annals of the New York Academy of Sciences

Volumn 902, Issue , 2000, Pages 272-282

  Loskutoff, David J ^a   Fujisawa, Kazuhiko ^a   Samad, Fahumiya ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; HORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL COUNT; CELL METABOLISM; CELL SIZE; CONFERENCE PAPER; CONTROLLED STUDY; GENE EXPRESSION; GENETIC MODEL; HEMOSTASIS; METABOLIC DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY;

ANIMALIA; STEATOMYS PRATENSIS;

EID: 0034043503     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06322.x     Document Type: Conference Paper

References (44)

1. 1. FINER, N. 1997. Obesity. Brit. Med. Bull. 53: 229-450.
2. 2. NIELSEN, S. & M.D. JENSEN. 1997. Obesity and cardiovascular disease: is body structure a factor? Curr. Opin. Lipidol. 8: 200-204.
3. 3. SPIEGELMAN, B.M. & J.S. FLIER. 1996. Adipogenesis and obesity: Rounding out the big picture. Cell 87: 377-389.
4. 4. DONG, Z.M., J.C. GUTIERREZ-RAMOS et al. 1997. A new class of obesity genes encodes leukocyte adhesion receptors. Proc. Natl. Acad. Sci. USA 94: 7526-7530.
5. 5. SPRENGERS, E.D. & C. KLUFT. 1987. Plasminogen activator inhibitors. Blood 69: 381-387.
6. 6. VAN MEIJER, M. & H. PANNEKOEK. 1995. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: An update. Fibrinolysis 9: 263-276.
7. 7. FEARNS, C., F. SAMAD et al. 1995:Synthesis and localization of PAI-1 in the vessel wall. In Vascular Control of Hemostasis. V.W.M. Van Hinsbergh, Ed.: 207-226. Harwood Academic Publishers. Amsterdam.
8. 8. LAWRENCE, D.A. & D. GINSBURG. 1996. Gene expression and function of plasminogen activator inhibitor-1. In Fibrinolysis in Disease: Molecular and Hemovascular Aspects of Fibrinolysis. P. Glas-Greenwalt, Ed.: 21-29. CRC Press Inc. Boca Raton, FL.
9. 9. CARMELIET, P. & D. COLLEN. 1997. Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. Curr. Opin. Lipidol. 8: 118-125.
10. 10. BRUCKERT, E., A. ANKRI et al. 1994. Relation between plasminogen activator inhibitor-1 and hepatic enzyme concentrations in hyperlipidemic patients. Thromb. Haemostas. 72: 434-437.
11. 11. FRIEDERICH, P.W., M. LEVI et al. 1997. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 96: 916-921.
12. 12. SAWDEY, M.S. & D.J. LOSKUTOFF. 1991. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J. Clin. Invest. 88: 1346-1353.
13. 13. JUHAN-VAGUE, I. & M.C. ALESSI. 1997. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb. Haemost. 78: 656-660.
14. 14. CALLES-ESCANDON, J., D. BALLOR et al. 1996. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am. J. Clin. Nutr. 64: 7-11.
15. 15. AILHAUD, G., P. GRIMALDI et al. 1992. A molecular view of adipose tissue. Int. J. Obes. 16: S17-S21.
16. 16. SAMAD, F., K. YAMAMOTO et al. 1996. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: Induction by tumor necrosis factor-a and lipopolysaccharide. J. Clin. Invest. 97: 37-46.
17. 17. SAMAD, F. & D.J. LOSKUTOFF. 1996. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol. Med. 2: 568-582.
18. 18. SAMAD, F., K. YAMAMOTO et al. 1997. Elevated expression of transforming growth factor-b in adipose tissue from obese mice, Mol. Med. 3: 37-48.
19. 19. ZHANG, Y., R. PROENCA et al. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432.
20. 20. SHIMOMURA, I., T. FUNAHASHI et al. 1996. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nature Med. 2: 800-803.
21. 21. LUNDGREN, C.H., S.L. BROWN et al. 1996. Elaboration of type-1 plasminogen activator inhibitor from adipocyte - A potential pathogenetic link between obesity and cardiovascular disease. Circulation 93: 106-110.
22. 22. ALESSI, M.C., F. PEIRETTI et al. 1997. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 46: 860-867.
23. 23. CIGOLINI, M., M. TONOLI et al. 1999. Expression of plasminogen activator inhibitor-1 in human adipose tissue: A role for TNF-α. Atherosclerosis 143: 81-90.
24. 24. EHRMANN, D.A., D.J. SCHNEIDER et al. 1997. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82: 2108-2116.
25. 25. NORDT, T.K., H. SAWA et al. 1995. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 91: 764-770.
26. 26. CARMASSI, F., M. MORALE, L. FERRINI, G. DELL'OMO, M. FERDEGHINI, R. PEDRINELLI & F. DE NEGRI. 1999. Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects. Am. J. Med. 107: 344-350.
27. 27. JAIN, S.K., D.K. NAGI et al. 1993. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabetic Med. 10: 27-32.
28. 28. NAGI, D.K., T.J. HENDRA et al. 1990. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factor in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 33: 532-537.
29. 29. LORMEAU, B., M.H. AUROUSSEAU et al. 1997. Hyperinsulinemia and hypofibrinolysis: Effects of short-term optimized glycemic control with continuous insulin infusion in Type II diabetic patients. Metabolism 46: 1074-1079.
30. 30. ALESSI, M.C., F. ANFOSSO et al. 1995. Up-regulation of PAI-1 synthesis by insulin and proinsulin in HEP G2 cells but not in endothelial cells. Fibrinolysis 9: 237-242.
31. 31. NORDT, T.K., D.J. SCHNEIDER et al. 1994. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: A potential risk factor for vascular disease. Circulation 89: 321-330.
32. 32. FUJII, S. & B.E. SOBEL. 1990. Induction of plasminogen activator inhibitor by products released from platelets. Circulation 82: 1485-1493.
33. 33. ARRANTS, J. 1994. Hyperinsulinemia and cardiovascular risk. Heart Lung 23: 118-122.
34. 34. BORDER, W.A. 1994. Transforming growth factor-beta and the pathogenesis of glomerular diseases. Curr. Opin. Nephrol. Hypertens. 3: 54-58.
35. 35. SHARMA, K. & F.N. ZIYADEH. 1995. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44: 1139-1146.
36. 36. HOTAMISLIGIL, G.S., N.S. SHARGILL et al. 1993. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 259: 87-91.
37. 37. HOTAMISLIGIL, G.S., P. ARNER et al. 1995. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
38. 38. HOTAMISLIGIL, G.S. & B.M. SPIEGELMAN. 1994. Tumor necrosis factor α: A key component of the obesity-diabetes link. Diabetes 43: 1271-1278.
39. 39. SAMAD, F., K.T. UYSAL, S.M. WIESBROCK, M. PANDEY, G.S. HOTAMISLIGIL & D.J. LOSKUTOFF. 1999. Tumor necrosis factor-α is a key component in the obesity-linked elevation of plasminogen activator inhibitor-1. Proc. Natl. Acad. Sci. USA (In press).
40. 40. EDGINGTON, T.S., C.D. DICKINSON et al. 1997. The structural basis of function of the TFxVIIa complex in the cellular initiation of coagulation. Thromb. Haemostas. 78: 401-405.
41. 41. MEADE, T.W., V. RUDDOCK et al. 1993. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342: 1076-1079.
42. 42. JUHAN-VAGUE, I., M.C. ALESSI et al. 1996. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann. Med. 28: 371-380.
43. 43. KARIO, K., T. MATSUO et al. 1995. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler. Thromb. Vasc. Biol. 15: 1114-1120.
44. 44. SAMAD, F., M. PANDEY et al. 1998. Tissue factor gene expression in the adipose tissues of obese mice. Proc. Natl. Acad. Sci. USA 95: 7591-7596.